M
Maria Michelagnoli
Researcher at University College London
Publications - 3
Citations - 347
Maria Michelagnoli is an academic researcher from University College London. The author has contributed to research in topics: Bone scintigraphy & Pegylated interferon. The author has an hindex of 2, co-authored 3 publications receiving 283 citations.
Papers
More filters
Journal ArticleDOI
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Gordana Jovic,Jane Hook,Mark Krailo,Mark C. Gebhardt,Zsuzsanna Papai,James O. Meyer,Helen Nadel,R. Lor Randall,Claudia Deffenbaugh,Rajaram Nagarajan,Bernadette Brennan,G. Douglas Letson,Lisa A. Teot,Allen M. Goorin,Daniel Baumhoer,Leo Kager,Mathias Werner,Ching C. Lau,Kirsten Sundby Hall,Hans Gelderblom,Paul A. Meyers,Richard Gorlick,Reinhard Windhager,Knut Helmke,Mikael Eriksson,Peter M. Hoogerbrugge,Paula J. Schomberg,Per-Ulf Tunn,Thomas Kühne,Heribert Jürgens,Henk van den Berg,Tom Böhling,Susan Picton,Marleen Renard,Peter Reichardt,Joachim Gerss,Trude Butterfass-Bahloul,Carol D. Morris,Pancras C.W. Hogendoorn,Beatrice Seddon,Gabriele Calaminus,Maria Michelagnoli,Catharina Dhooge,Matthew R. Sydes,Mark L. Bernstein +48 more
TL;DR: Investigation of maintenance therapy with pegylated interferon alfa-2b in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy found that MAP plus IFN-α-2B was not statistically different from MAP alone.
Journal ArticleDOI
Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.
Sandra J. Strauss,Anne McTiernan,D. Driver,Margaret A Hall-Craggs,A. Sandison,A Cassoni,A. Kilby,Maria Michelagnoli,J. Pringle,Justin Cobb,Timothy W. R. Briggs,S Cannon,J. D. Witt,Jeremy Whelan +13 more
TL;DR: V VIDE is an effective induction regimen with substantial but acceptable toxicity that allows predictable mobilization of stem cells and maintenance of dose-intensity is feasible in the majority of patients.
Journal ArticleDOI
Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)
Katrina M. Ingley,Simon Wan,Stefan Vöö,Rachael Windsor,Maria Michelagnoli,Asif Saifuddin,Sandra J. Strauss +6 more
TL;DR: In this article, the authors conclude that BMB is no longer required for the staging of Ewing sarcoma as it does not influence the standard of care management, however, BMB may provide prognostic information and insights into the biology of ES in selected patients.